Reconciling the divergent findings from clinical trials and observational studies of menopausal hormone therapy for prevention of coronary heart disease

Seminars in Reproductive Medicine

Volumn 32, Issue 6, 2014, Pages 426-432

  Rossouw, Jacques E ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

clinical trials; coronary heart disease; epidemiology; estrogen; progestin

Indexed keywords

ESTROGEN; GESTAGEN;

AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CONFOUNDING VARIABLE; DISEASE ASSOCIATION; ESTROGEN THERAPY; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LONG TERM CARE; MEDICAL SOCIETY; MEDICATION COMPLIANCE; MENOPAUSAL HORMONE THERAPY; MENOPAUSE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SHORT COURSE THERAPY; TREATMENT DURATION; WOMEN HEALTH INITIATIVE; ADVERSE EFFECTS; AGING; CHEMICALLY INDUCED; COMPARATIVE STUDY; CORONARY DISEASE; EPIDEMIOLOGY; FEMALE; REPRODUCIBILITY; UNITED STATES; WOMEN'S HEALTH;

AGING; CONFOUNDING FACTORS (EPIDEMIOLOGY); CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; OBSERVATIONAL STUDY AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RISK FACTORS; UNITED STATES; WOMEN'S HEALTH;

EID: 84912132943     PISSN: 15268004     EISSN: 15264564     Source Type: Journal    
DOI: 10.1055/s-0034-1384625     Document Type: Article

References (20)

1. Tsai S. A., Stefanick M. L., Stafford R. S. Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause: 2011; 18 4 385 392
2. Grady D., Rubin S. M., Petitti D. B., et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med: 1992; 117 12 1016 1037
3. Barrett-Connor E., Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health: 1998; 19 55 72
4. Rossouw J. E., Anderson G. L., Prentice R. L., et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA: 2002; 288 3 321 333
5. Anderson G. L., Limacher M., Assaf A. R., et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA: 2004; 291 14 1701 1712
6. Rossouw J. E., Prentice R. L., Manson J. E., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA: 2007; 297 13 1465 1477
7. North American Menopause Society The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause: 2012; 19 3 257 271
8. Michels K. B., Manson J. E. Postmenopausal hormone therapy: a reversal of fortune. Circulation: 2003; 107 14 1830 1833
9. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA: 1998; 280 7 605 613
10. Grodstein F., Manson J. E., Stampfer M. J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt): 2006; 15 1 35 44
11. Mendelsohn M. E., Karas R. H. HRT and the young at heart. N Engl J Med: 2007; 356 25 2639 2641
12. Manson J. E., Allison M. A., Rossouw J. E., et al. WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. N Engl J Med: 2007; 356 25 2591 2602
13. Hsia J., Langer R. D., Manson J. E., et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med: 2006; 166 3 357 365
14. Prentice R. L., Langer R., Stefanick M. L., et al. Women's Health Initiative Investigators. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol: 2005; 162 5 404 414
15. Prentice R. L., Langer R. D., Stefanick M. L., et al. Women's Health Initiative Investigators. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol: 2006; 163 7 589 599
16. Prentice R. L., Manson J. E., Langer R. D., et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol: 2009; 170 1 12 23
17. Rossouw J. E., Prentice R. L., LaCroix A. Z., et al. Hormone therapy and cardiovascular risk-reply. JAMA: 2007; 298 623 625
18. Hernán M. A., Alonso A., Logan R., et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology: 2008; 19 6 766 779
19. Heiss G., Wallace R., Anderson G. L., et al. WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA: 2008; 299 9 1036 1045
20. Toh S., Hernández-Díaz S., Logan R., Rossouw J. E., Hernán M. A. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med: 2010; 152 4 211 217